Cargando…

Role of Immune Checkpoint Inhibitors in Gastrointestinal Malignancies

Immune checkpoint inhibitors (ICIs) have revolutionized the treatment of several solid and hematological malignancies. ICIs are not only able to produce long and durable responses, but also very well tolerated by patients. There are several approved indications of use of ICIs in treatment of metasta...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mazloom, Anita, Ghalehsari, Nima, Gazivoda, Victor, Nimkar, Neil, Paul, Sonal, Gregos, Peter, Rateshwar, Janice, Khan, Uqba
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2020
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7463795/ https://www.ncbi.nlm.nih.gov/pubmed/32781500 http://dx.doi.org/10.3390/jcm9082533

Ejemplares similares

ABO Blood Type and Outcomes in a Diverse COVID-19 Infected Population
por: Paul, Sonal, et al.
Publicado: (2020)

Outcomes in COVID-19 Patients on Treatment Dose Anti-Coagulation Compared to Prophylactic Dose Anti-Coagulation
por: Kodama, Rich, et al.
Publicado: (2020)

Evaluation of Antiplatelet and Anticoagulation Therapy in High-Risk COVID-19 Patients
por: Ashraf, Farah, et al.
Publicado: (2020)

COVID-19 Prognostic Score Utilizing Hematological and Inflammatory Markers to Determine Outcomes of Hospitalized Patients
por: Kalsi, Amardeep, et al.
Publicado: (2020)

Clinical Course and Outcomes of Sickle Cell Disease Patients with COVID-19 at a New York Hospital
por: Mazloom, Anita, et al.
Publicado: (2020)

Immune Checkpoint Inhibitors for Gastrointestinal Malignancies: An Update
por: DeCarli, Kathryn, et al.
Publicado: (2022)

Impact of corticosteroid therapy on the outcomes of hepatocellular carcinoma treated with immune checkpoint inhibitor therapy
por: Pinato, David J, et al.
Publicado: (2020)

Immune checkpoint inhibitor-mediated colitis in gastrointestinal malignancies and inflammatory bowel disease
por: Weingarden, Alexa R, et al.
Publicado: (2021)

Immune checkpoint inhibitor-related gastrointestinal toxicity in patients with malignancy involving the luminal gastrointestinal tract and its impact on cancer outcomes
por: Yu, Kevin, et al.
Publicado: (2022)

Role of Checkpoint Inhibitors in the Management of Gastroesophageal Cancers
por: Karim, Frederic, et al.
Publicado: (2023)

Combination regimens with PD-1/PD-L1 immune checkpoint inhibitors for gastrointestinal malignancies
por: Wang, Dongxu, et al.
Publicado: (2019)

Current Status of Immune Checkpoint Inhibitors in Gastrointestinal Cancers
por: Kim, Bum Jun, et al.
Publicado: (2017)

Biomarkers for response to immune checkpoint inhibitors in gastrointestinal cancers
por: Li, Meng, et al.
Publicado: (2022)

Immune Checkpoint Inhibitors to Treat Malignant Lymphomas
por: Witkowska, Magdalena, et al.
Publicado: (2018)

Toxicity of Immune-Checkpoint Inhibitors in Hematological Malignancies
por: Hradska, Katarina, et al.
Publicado: (2021)

The efficacy of immune checkpoint inhibitors in thoracic malignancies
por: Remon, Jordi, et al.
Publicado: (2021)

Patterns and outcomes of subsequent therapy after immune checkpoint inhibitor discontinuation in HCC
por: Sharma, Rohini, et al.
Publicado: (2022)

Management of gastrointestinal adverse events induced by immune-checkpoint inhibitors
por: Wang, Zheng-Hang, et al.
Publicado: (2018)

Gastrointestinal adverse events associated with immune checkpoint inhibitor therapy
por: Rajha, Eva, et al.
Publicado: (2019)

Immune checkpoint inhibitors in malignant lymphoma: Advances and perspectives
por: Lin, Ningjing, et al.
Publicado: (2020)

Immune checkpoint inhibitor-associated gastrointestinal and hepatic adverse events and their management
por: Shivaji, Uday N., et al.
Publicado: (2019)

Gastrointestinal toxicities of immune checkpoint inhibitors: a multicenter retrospective analysis
por: Shieh, Christine, et al.
Publicado: (2021)

Immune Checkpoint Inhibitor-Induced Gastrointestinal Toxicity: The Opinion of a Gastroenterologist
por: Macovei Oprescu, Anca, et al.
Publicado: (2021)

Characteristics and Prognosis of Acquired Resistance to Immune Checkpoint Inhibitors in Gastrointestinal Cancer
por: Zhuo, Na, et al.
Publicado: (2022)

Targeting myeloid villains in the treatment with immune checkpoint inhibitors in gastrointestinal cancer
por: Kudo-Saito, Chie, et al.
Publicado: (2022)

Current Immune Checkpoint Inhibitor Genetic Biomarker Exploration in Gastrointestinal Tumors
por: Rogers, Jane E., et al.
Publicado: (2022)

Infectious complications of immune checkpoint inhibitors in solid organ malignancies
por: Ross, Justine Abella, et al.
Publicado: (2021)

What is the optimal duration of immune checkpoint inhibitors in malignant tumors?
por: Yin, Jiaxin, et al.
Publicado: (2022)

The Evolving Role of Immune-Checkpoint Inhibitors in Malignant Pleural Mesothelioma
por: Borgeaud, Maxime, et al.
Publicado: (2023)

Checkpoint inhibitors in hematological malignancies
por: Ok, Chi Young, et al.
Publicado: (2017)

Current status of treatment with immune checkpoint inhibitors for gastrointestinal, hepatobiliary, and pancreatic cancers
por: Eso, Yuji, et al.
Publicado: (2020)

A Review of Emerging Biomarkers for Immune Checkpoint Inhibitors in Tumors of the Gastrointestinal Tract
por: Liao, Xuqiang, et al.
Publicado: (2022)

Immune checkpoint inhibitors-associated cardiotoxicity in immunotherapy trials on gastrointestinal cancer patients
por: Li, Yiqun, et al.
Publicado: (2022)

A Curious Case of Gastrointestinal Eosinophilia Induced by Treatment With Immune Checkpoint Inhibitors
por: Reddy, Yala Kirthi, et al.
Publicado: (2023)

Clinical characteristics of gastrointestinal immune-related adverse events of immune checkpoint inhibitors and their association with survival
por: Yamada, Kentaro, et al.
Publicado: (2021)

Cytomegalovirus Infections in Patients Treated With Immune Checkpoint Inhibitors for Solid Malignancies
por: Anastasopoulou, Amalia, et al.
Publicado: (2023)

Checkpoint inhibitors in gastrointestinal cancers: Expectations and reality
por: Kourie, Hampig Raphael, et al.
Publicado: (2017)

Checkpoint inhibitors in the treatment of urological malignancies
por: Popovic, Lazar S, et al.
Publicado: (2017)

Redefine Hyperprogressive Disease During Treatment With Immune-Checkpoint Inhibitors in Patients With Gastrointestinal Cancer
por: Wang, Zhenghang, et al.
Publicado: (2021)

Gastrointestinal Toxicities of Immune Checkpoint Inhibitors Are Associated With Enhanced Tumor Responsiveness and Improved Survival
por: Alomari, Mohammad, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_rkganos94dnbhg37j8tus9u6mp